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Quality-of-life improvement after endoscopic sinus surgery
in patients with obstructive sleep apnea
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Joseph S. Schwartz, M.D.,2 Jeffrey D. Suh, M.D.,3 James N. Palmer, M.D.,2 and
Nithin D. Adappa, M.D.2
ABSTRACT
Background: There is preliminary evidence that patients with chronic rhinosinusitis (CRS) and comorbid obstructive sleep
apnea (OSA) have reduced quality-of-life (QOL) improvements after functional endoscopic sinus surgery (FESS) compared
with patients without OSA. The effect of OSA severity on QOL improvement after FESS is unknown.
Objectives: To better characterize the QOL improvement after FESS for patients with comorbid OSA and to assess whether
QOL improvement is dependent on OSA severity.
Methods: This multi-institution, retrospective cohort study evaluated adult patients with CRS who underwent FESS
between 2007 and 2015. Preoperative, 1-month, 3-month, 6-month, and 1-year postoperative 22-Item Sino-Nasal Outcome Test
scores were used to evaluate QOL. We compared patients without OSA with patients with stratified OSA based on the
preoperative apnea-hypopnea index. A multilevel, mixed-effects linear regression model was used for the analysis.
Results:Of 480 participants, 83 (17%) had OSA, and 47 of these patients had polysomnography results available for review.
Both patients with OSA and patients without OSA reported significant QOL improvement after surgery (p  0.0001) relative
to baseline. In the unadjusted model, the subjects with OSA demonstrated a statistically worse outcome in 22-Item Sino-Nasal
Outcome Test scores at each time point (2.4 points higher per time point, p  0.006). When controlling for covariates, the
adjusted model showed no difference in QOL outcome based on OSA status (p  0.114). When stratified by OSA disease
severity, the adjusted model showed no difference in the QOL outcome.
Conclusions: Patients with CRS and comorbid OSA had worse QOL outcomes after FESS; however, when controlling for
patient factors, there was no difference in QOL outcome. OSA disease severity did not seem to predict QOL improvement after
FESS.
(Allergy Rhinol 8:e25–e31, 2017; doi: 10.2500/ar.2017.8.0195)
A growing body of evidence has linked the pres-ence of both obstructive sleep apnea (OSA)
and chronic rhinosinusitis (CRS) to greater deterio-
ration in patient well-being.1 Independently, CRS
and OSA have a well-documented societal and indi-
vidual impact. CRS has been associated with decre-
ments in quality of life (QOL) and reduced produc-
tivity that led to significant economic burden to
society and the health systems required to the alle-
viate the symptoms of CRS.2–4 Similarly, OSA affects
sleep quality and is associated with daytime sleepi-
ness and diminished cognitive performance. It is
recognized as a major health issue, with potential
societal consequences that lead to accidents, de-
creased work efficiency, and morbidity from card-
iopulmonary sequelae.5 Both diseases have been
found to contribute to significant sleep dysfunction,
and patients with comorbid disease report worse
QOL.6
Functional endoscopic sinus surgery (FESS) is an
accepted treatment for medically recalcitrant CRS with
documented QOL improvement after surgery.7,8 A re-
cent study showed that, in patients with CRS and
comorbid OSA, QOL improvement can be achieved
with FESS, albeit to a lesser extent than in patients with
CRS alone.1 Although improvement has been shown,
an analysis of QOL trajectories has not been described.
In addition, the effect of OSA disease severity has not
been investigated. Herein we aimed to perform the
largest analysis of QOL outcome in patients with co-
morbid OSAwho were undergoing FESS. Longitudinal
linear mixed-effects modeling was used to capture all
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the data and provide a comprehensive analysis of QOL
outcomes among patients with CRS and with and
without OSA. In addition, we aimed to examine the
impact of OSA disease severity on QOL after FESS
based on the apnea-hypopnea index (AHI).
METHODS
A retrospective cohort study was performed on
515 patients who underwent FESS between April 19,
2007, and October 12, 2015, at the involved tertiary
care academic medical centers. Eligibility included
age 18 years and patients undergoing FESS for
medically recalcitrant CRS. Exclusion criteria in-
cluded having a known autoimmune disorder or
immunodeficiency, primary ciliary dyskinesia, cystic
fibrosis, history of therapeutic radiation exposure to
the paranasal sinuses, sinonasal tumor or malig-
nancy, skull base encephalocele or cerebrospinal
fluid leak, or a history of sinonasal trauma. Thirty-
five patients were excluded due to these criteria. In
total, 480 patients were eligible for analysis. All
study protocols and informed consents were col-
lected and approved by the institutional review
board at both tertiary care centers.
The 22-Item Sinonasal Outcome Test (SNOT-22) was
given to every patient in the study at each visit. Com-
pleted questionnaires before surgery and then at 1-,
3-, 6-, and 12-month intervals were used for statistical
analysis. Of the 480 patients, there were a total of 1523
completed SNOT-22 forms over the five time points.
The SNOT-22 is a well-validated disease-specific QOL
questionnaire, with a high Cronbach alpha (  0.91)
and has a test-retest reliability of 0.93.9 Psychometric
validity research by Hopkins et al.9 found the mini-
mally clinically important difference that is the small-
est change in SNOT-22 score that can be detected by a
patient to be 8.9 points. Baseline characteristics in-
cluded sociodemographic information, comorbidities,
and Lund-MacKay computed tomography (CT) scores.
Sociodemographic data were collected by a combina-
tion of chart review and patient self-report. Comorbidi-
ties were assessed by chart review of the preoperative
reports at the time of surgery. All the chart reviews
were independently entered into a data base by two
independent research personnel and then checked for
agreement (S.G.B, C.H.Y.). Lund-MacKay computed
tomography scores were scored from 0 to 2 for six
bilateral areas of sinus opacification for a possible score
of between 0 and 24. A higher Lund-MacKay com-
puted tomography score indicates greater severity of
CRS.
Statistical Analysis
Distributions for demographic and clinical variables,
including comorbidities, surgery history, and preoper-
ative scores, were compared by OSA group by using
Fisher exact tests for categorical variables and general
linear models for continuous variables. Longitudinal
linear mixed-effects modeling was used to examine the
relationship between SNOT-22 and OSA status. The
distribution of the SNOT-22 measure follows a uni-
modal symmetric distribution and satisfies the as-
sumptions for mixed-effects modeling. Mixed-effects
modeling takes advantage of all available data (up to
the point of loss to follow-up or withdrawal) and also
can address missing data. Because the level of missing-
ness was not excessive and patterns of missingness
were not detected, the mixed-effects modeling relied
on all available data.10–13 Both random slopes and
intercepts were modeled to represent the subject-level
deviation from the average slope over time and inter-
cept.
Restricted maximum likelihood estimation was
used, along with an unstructured covariance struc-
ture. The outcome was analyzed as repeated obser-
vations (five assessments over 1 year at before sur-
gery and 1, 3, 6 and 12 months after surgery). Time
was measured as a continuous variable. An unad-
justed mixed-effects model was estimated by re-
gressing longitudinal outcome on time, OSA status,
and the OSA time interaction. Then an adjusted
model was built by considering potential fixed ef-
fects (e.g., age, sex) identified by using simple main
effects and two-way interaction-with-time models
based on an inclusion criterion, p  0.20.12,14 An
initial multivariable mixed-effects model was con-
structed by using all of the aforementioned signifi-
cant two-way interaction-with-time covariates, along
with the corresponding main effects.
By using this full model, interactions were sequen-
tially eliminated based on least significance until
only interaction effects that demonstrated p  0.20
remained.12,14 Covariates that were not included in
the aforementioned final interaction model but dem-
onstrated p  0.20 in simple main-effects models
were then added to the final multivariable interac-
tion model and assessed sequentially as described
earlier. With the exception of the OSA group, time,
and the two-way interaction between OSA group
and time (which were forced into the model), the
final multivariable model only included covariates
and interaction terms that demonstrated significance
at the p  0.20 level. Patients with OSA were then
broken into groups of normal, mild, moderate, and
severe based on AHI score by using all available
sleep study data to investigate possible differences
in postoperative outcomes between AHI stratum.
Forty-nine of the 83 patients with OSA had sleep
study data (Table 1). Unadjusted and adjusted lon-
gitudinal linear mixed-effects models were also fit-
ted for this categorical predictor by using the same
e26 March 2017, Vol. 8, No. 1
model-building method. All statistical analyses were
carried out by using Stata 13.1/IC (StataCorp, LP,
College Station, TX). Alpha was set at 0.05 (two-
tailed).
RESULTS
Baseline Characteristics
Patients with OSA versus their non-OSA counter-
parts were found to be more commonly male patients
(45 versus 29%), diabetic (22 versus 6%), older age (55
versus 49 years), and higher body mass index (32 ver-
sus 27 kg/m2) (Table 2). The overall cohort was 88%
white, 9% African American, and 3% other. Patients
with OSA did not differ significantly from patients
without OSA in preoperative sinus disease severity or
in disease-specific QOL. There also were no observed
differences in primary versus revision surgery status
between the groups (Table 3).
Table 1 AHI by category
AHI category OSA, no. of patients
(%) (n  49 11%)
No OSA, no. of patients
(%) (n  397 89%)
Total, no. of patients
(%) (N  446)
Normal (5) 2 (4.1) 397 (100) 399 (89.5)
Mild (5 and 15) 12 (24.5) 0 (0) 12 (2.7)
Moderate (15 and 30) 16 (32.7) 0 (0) 16 (3.6)
Severe (30) 19 (38.8) 0 (0) 19 (4.3)
AHI  Apnea-hyponea index; OSA  obstructive sleep apnea.
Table 2 Demographic and clinical covariates
Total OSA (n  83 17.3%) No OSA (n  397 82.7%) p
Demographics, no. (%)
Female patients 203 (42.3) 24 (28.9) 179 (45.1) 0.007
Race 0.672
White 416 (88.3) 66 (86.8) 350 (88.6) —
Black 42 (8.9) 7 (9.2) 35 (8.9) —
Other 13 (2.8) 3 (4.0) 10 (2.5) —
Smoker 0.881
Never 268 (56.8) 46 (55.4) 222 (57.1) —
Former 165 (35.0) 31 (37.4) 134 (34.5) —
Current 39 (8.3) 6 (7.2) 33 (8.5) —
Comorbidities, no. (%)
Allergic fungal sinusitis 27 (5.6) 5 (6.0) 22 (5.5) 0.796
Diabetes mellitus 43 (9.0) 18 (21.7) 25 (6.3) 0.001
GERD 147 (30.6) 28 (33.7) 119 (30.0) 0.514
Polyps 270 (57.5) 42 (51.9) 228 (58.6) 0.269
AERD 68 (14.2) 8 (9.6) 60 (15.1) 0.228
Age at surgery, mean (SD), y 49.7  14.1 55.0  12.7 48.6  14.1 0.001
BMI, mean (SD), kg/m2 28.2  5.3 32.3  5.9 27.4  4.8 0.001
Preoperative scores, mean (SD)
SNOT-22 total score 44.4  21.8 43.8  20.2 44.5  22.2 0.791
Rhinologic symptoms 15.2  7.1 13.9  7.3 15.5  7.0 0.065
Extranasal symptoms 7.6  4.0 7.0  4.3 7.7  4.0 0.157
Ear/facial symptoms 7.6  5.2 6.9  5.0 7.7  5.2 0.174
Psychological symptoms 11.9  9.2 13.0  8.1 11.6  9.4 0.258
Sleep symptoms 11.2  7.6 12.3  6.6 11.0  7.8 0.184
Lund-MacKay CT score 12.4  5.5 11.9  4.9 12.4  5.6 0.483
OSA  Obstructive sleep apnea; GERD  gastroesophageal reflux disease; AERD  aspirin-exacerbated respiratory disease;
SD  standard deviation; BMI  body mass index; SNOT-22  22-Item Sino-Nasal Outcome Test; CT  computed
tomography.
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Longitudinal Outcomes
There were no significant differences between the
groups in terms of completed SNOT-22 forms at any of
the five time points. Results from the unadjusted and
adjusted longitudinal linear mixed-effects model by
using the dichotomous OSA variable (OSA versus non
OSA) as the predictor of interest are provided in Table
4. SNOT-22 scores were significantly lower than the
baseline score for all the patients (a 6.00-point decrease
per time point, p  0.001). In the unadjusted model,
the subjects with OSA demonstrated a statistically
worse predicted outcome in SNOT-22 scores over the
12-month follow-up period relative to patients with-
out OSA (2.4 points higher per time point, p  0.006).
This trend was seen in every subscale of the
SNOT-22 in the unadjusted model as well (Table 4).
In the adjusted model, no differences were seen be-
tween the groups. The adjusted model for the “extra-
nasal” subscale demonstrated differences between
patients with OSA and patients without OSA of ap-
proximately half a point for each follow-up time point
(p  0.002). Longitudinal linear mixed-effects models
were also fit for the categorical predictor of AHI category
(Table 5). A similar trend was seen in these models as
well, in which the unadjusted model showed significant
differences between normal (AHI score of 5) and all
other groups (p  0.002), and, in the adjusted model, no
significant differences were seen.
DISCUSSION
OSA is a potentially debilitating chronic medical
condition that has increased in prevalence over time.
The prevalence of OSA in our study cohort was found
to be 17%, which was similar to the reported preva-
lence of OSA in the general U.S. population.15 In addi-
tion, more patients with OSA were male patients, (p 
0.007), consistent with published estimates.16 Baseline
data also revealed that patients with OSA were older
(p  0.001), had a higher body mass index (p  0.001),
and more commonly had diabetes (p  0.001). Baseline
SNOT-22 scores were no different between the patients
with CRS and those with comorbid OSA (p 0.791). This
held true across the five subdomains of the SNOT-22
(Table 2). Intriguingly, the patients with CRS andwithout
OSA experienced similar sleep disturbance when com-
pared with the patients with comorbid OSA as measured
by the sleep disturbance subdomain (p  0.184), which
Table 3 The number of previous surgeries
Surgeries Total, no. of patients (%) OSA, no. of patients (%) No OSA, no. of patients (%) p
0.876
Primary 162 (34.0) 28 (33.7) 134 (34.1) —
Previous
1 144 (30.3) 24 (28.9) 120 (30.5) —
2 83 (17.4) 17 (20.5) 66 (16.8) —
3 87 (18.3) 14 (16.9) 73 (18.6) —
OSA  Obstructive sleep apnea.
Table 4 Unadj. and adj. mixed model: OSA status—SNOT-22 total scores
Coefficient  SE p 95% CI
Unadj. Adj. Unadj. Adj. Unadj. Adj. Unadj. Adj.
Main effects: Time 	6.00 	6.26 0.35 1.58 0.001 0.001 	6.70 to 	5.31 	9.37 to 	3.16
Interaction:
OSA*time
2.40 1.67 1.00 1.06 0.006 0.114 0.70–4.10 	0.40 to 3.74
Subscale interaction
term
Rhinologic 0.68 0.63 0.30 0.37 0.025 0.091 0.08–1.27 	0.10 to 1.36
Extranasal 0.48 0.58 0.17 0.19 0.005 0.002 0.15–0.82 0.21–0.94
Ear/facial 0.48 0.25 0.18 0.18 0.007 0.179 0.13–0.84 	0.11 to 0.61
Psychological 0.79 0.30 0.31 0.36 0.010 0.395 0.19–1.39 	0.40 to 1.00
Sleep 0.62 0.51 0.28 0.34 0.026 0.132 0.07–1.17 	0.15 to 1.18
Unadj. Unadjusted; adj. adjusted; OSA obstructive sleep apnea; SNOT-22 22-Item Sino-Nasal Outcome Test; SE
standard error; CI  confidence interval.
e28 March 2017, Vol. 8, No. 1
was in agreement with literature that supports abnormal
sleep quality in patients with CRS.6
All the patients showed significant improvement af-
ter FESS (p  0.001). The QOL trajectories of the study
groups with inclusion of the adjusted model are dem-
onstrated in Fig. 1. As shown, there was significant
improvement in the total SNOT-22 score at each test
interval among all the groups; however, the patients
with OSA showed less improvement than patients
without comorbid OSA (p  0.006). By using the linear
regression model, patients with OSA would be ex-
pected to have a clinically significant higher SNOT-22
score at 12 months (9.6 points) when compared with
patients without OSA.9 When controlling for covari-
Table 5 Unadj. and adj. mixed model: OSA by AHI category—SNOT-22 total scores
Coefficient  SE p 95% CI
Unadj. Adj. Unadj. Adj. Unadj. Adj. Unadj. Adj.
Main effects
Time 	6.00 	5.53 0.35 1.64 0.001 0.001 	6.69 to 	5.31 	8.73 to 2.32
Interaction
Overall interaction
term
— — — — 0.002 0.173 — —
Mild*time 3.48 4.37 2.03 2.65 0.087 0.099 	0.50 to 7.47 	0.82 to 9.56
Moderate*time 5.96 3.78 1.69 2.52 0.001 0.134 2.65–9.28 	1.16 to 8.72
Severe*time 1.27 0.88 1.52 1.94 0.407 0.652 	1.72 to 4.26 	2.93 to 4.68
Unadj.  Unadjusted; adj.  adjusted; OSA  obstructive sleep apnea; AHI  apnea-hypopnea index; SNOT-22  22-Item
Sino-Nasal Outcome Test; SE  standard error; CI  confidence interval.
Figure 1. Quality-of-life trajectories among the study groups, with inclusion of the adjusted model.
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ates, the adjusted model revealed no difference in QOL
outcome between the patients with OSA and the pa-
tients without OSA (p  0.114). This is depicted in Fig.
1, in which the QOL trajectory of the patients with OSA
in the adjusted model nearly overlapped with the tra-
jectory for the patients without OSA. In addition, this
finding held true for all subdomains, except the extra-
nasal subdomain (p  0.002); however, this effect was
small and represented only a half-point difference for
each follow-up time point.
Alt et al.1 performed the only other study to assess
QOL outcomes after FESS for patients with comorbid
OSA. They found that patients with comorbid OSA
demonstrated less improvement in SNOT-22 rhino-
logic symptom domain scores, which we did not dem-
onstrate in the current study.1 The disparity likely lies
in differences in methodology. In their study, improve-
ment was assessed by subtracting the preoperative
SNOT-22 score from the last available follow-up score
(with at least a 6-month follow-up evaluation).1 This
method does not allow for missing data and, therefore,
excluded patients who might have missed a response
but nonetheless completed baseline, 1-month, and
3-month questionnaires. To circumvent this, we elected
to use a mixed-effects model in our analysis to allow
inclusion of all data. In addition, the use of a mixed-
effects model takes into account within-subject vari-
ance. For example, if a patient had a preoperative
SNOT-22 score of 15 and a 6-month score of 0, then a
calculated difference of 15 was scored. This was a
considerably different outcome compared with a pa-
tient with a preoperative score of 100 and a 6-month
score of 85. As such, linear mixed-effects regression
modeling, as chosen for the current study, was more
appropriate for repeated-measures outcomes data be-
cause it further incorporates a random-effects term to
account for individual differences in the QOL trajec-
tory.
Analysis of the data reported in this work indicated
that, although patients with comorbid OSA had a re-
duced QOL outcome after FESS, this was the result of
comorbidities associated with OSA and not the effect
of OSA itself. OSA is a chronic condition characterized
by recurrent episodes of apnea or hypopnea that cause
intermittent hypoxemia and hypercapnia, oxidative
stress, and sleep fragmentation. OSA has been inde-
pendently associated with diabetes, hypertension, cor-
onary artery disease, stroke, depression, gastroesoph-
ageal reflux disease, and cardiovascular mortality.16
These associated comorbidities are likely the cause of
reduced QOL after FESS. Only a few studies delineated
how specific comorbidities affects QOL outcomes after
FESS. Zhang et al.17 showed that patients with diabetes
and comorbid CRS had worse QOL outcomes and
were more likely to have Pseudomonas aeruginosa infec-
tion and nasal polyps. Steele et al.,18 in their multi-
institutional treatment outcomes investigation, showed
that patients with comorbid obesity report reduced
QOL gains after FESS. Otherwise, the effect of premor-
bid cardiovascular disease on QOL outcomes after
FESS has yet to be clearly delineated.
Few reports exist regarding QOL outcomes based on
OSA severity. Dutt et al.,19 in their prospective study of
QOL outcomes in patients with OSA, showed no cor-
relation between QOL impairment and the severity of
OSA. This finding was also supported in three addi-
tional reports that used different measures of
QOL.20–22 Specific to sinonasal concerns, Kuan et al.23
found no correlation between AHI and SNOT-22
scores in patients with OSA and without CRS. To date,
no investigation has evaluated sleep apnea severity as
it relates to QOL outcomes after FESS. Our results
indicated no difference in QOL outcome after FESS
based on AHI grouping in the adjusted model (Table
5), which was consistent with the previous stated lit-
erature that indicated that the severity of QOL impair-
ment was independent of OSA severity. A larger sam-
ple size will be necessary to establish more definitive
relationships because only 47 patients with OSA had
complete polysomnography data for review.
CONCLUSION
Here we performed the largest study, to our knowl-
edge, that evaluated QOL outcomes after FESS in pa-
tients with CRS and sleep apnea. Patients with comor-
bid sleep apnea had worse QOL outcomes when
compared with patients without OSA; however, this
finding was not true when controlling for potential
confounding variables. In addition, there was no dif-
ference in QOL outcome when evaluating patients
based on OSA severity. The results in this study have
important clinical implications for physicians when
counseling patients with comorbid OSA regarding ex-
pected outcomes after FESS.
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